Copyright
©2012 Baishideng Publishing Group Co.
World J Gastrointest Pharmacol Ther. Aug 6, 2012; 3(4): 36-48
Published online Aug 6, 2012. doi: 10.4292/wjgpt.v3.i4.36
Published online Aug 6, 2012. doi: 10.4292/wjgpt.v3.i4.36
Ref. | Yr | Type of Study | Time since LT (mo) | n | Genotype (%) | Antiviral Therapy | SVR (%) | Discontinuation (%) |
Rodriguez-Luna et al[88] | 2004 | Prospective, uncontrolled | 4.2 | 19 | 63 | Peg-IFN 0.5-1.5 μg/kg/wk + RBV 400-1000 mg daily x 48 wk after neg. RNA | 26 | 49 |
Neff et al[89] | 2004 | Retrospective, uncontrolled | 23.5 | 57 | 98 | Peg-IFN 1.5 μg/kg/wk + RBV 400-600 mg daily x 48 wk | 14 | 32 |
Dumortier et al[97] | 2004 | Prospective, uncontrolled | 28 | 20 | 80 | Peg-IFN 0.5-1.0 μg/kg/wk + RBV 400-1200 mg daily x 48 wk | 45 | 20 |
Castells et al[107] | 2005 | Prospective, controlled | 3.8 | 24 | 100 | Peg-IFN 1.5 μg/kg/wk + RBV 400-800 mg daily x 48 wk | 35 | 13 |
Berenguer et al[102] | 2006 | Retrospective, uncontrolled | 16.6 | 36 | 89 | IFN and RBV/Peg-IFN and RBV | 18 | 40 |
Oton et al[103] | 2006 | Prospective, uncontrolled | 63.3 | 55 | 91 | Peg-IFN 180 μg/1.5 μg/kg/wk + RBV 11 mg/kg/d x 48 wk | 24 | 7 |
Mukherjee et al[104] | 2006 | Retrospective, uncontrolled | 16 | 32 | 75 | Peg-IFN 180 μg + RBV 1000-1200 mg daily x 48 wk | 34 | 15 |
Mukherjee et al[104] | 2006 | Prospective, uncontrolled | 20 | 39 | 79 | Peg-IFN 1.5 μg/kg/wk + RBV 800 mg daily x 6-12 mo | 33 | 43 |
Fernandez et al[105] | 2006 | Prospective, uncontrolled | 32 | 47 | 93 | Peg-IFN 1.5 μg/kg/wk + RBV 800-1000 mg daily x 48 wk | 23 | 21 |
Neumann et al[106] | 2006 | Prospective, uncontrolled | 38 | 25 | 80 | Peg-IFN 1.0 μg/kg/wk + RBV 600 mg daily x 48 wk | 36 | 4 |
Picciotto et al[94] | 2007 | Prospective, uncontrolled | 25 | 61 | 87 | Peg-IFN 1 μg/kg/wk RBV 600-800 mg daily x 6-12 mo | 28 | 15 |
Angelico et al[108] | 2007 | Prospective, controlled | 48 | 21 | 81 | Peg-IFN 180 μg + RBV 200-800 mg daily x 48 wk | 33 | 55 |
Carriòn et al[140] | 2007 | Prospective, controlled | 14.5 | 54 | 92 | Peg-IFN 1.5 μg/kg/wk + 400-1200 mg daily x 48 wk | 33 | 39 |
Sharma et al[141] | 2007 | Retrospective, uncontrolled | 16 | 35 | 77 | Peg-IFN 90-180 μg/0.5-1.5 μg/kg/wk + RBV 800 mg daily x 48 wk | 37 | 74 |
Zimmermann et al[107] | 2007 | Prospective, uncontrolled | 9.4 | 26 | 88 | 90 μg/wk for 4 wk then 135-180 μg/wk + 600 mg for 5 wk, then 800–1200 mg x 48 wk | 19 | 11 |
- Citation: Carbone M, Lenci I, Baiocchi L. Prevention of hepatitis C recurrence after liver transplantation: An update. World J Gastrointest Pharmacol Ther 2012; 3(4): 36-48
- URL: https://www.wjgnet.com/2150-5349/full/v3/i4/36.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v3.i4.36